We are live on
!
Find out more
ACM
Altium Capital Management Portfolio holdings
AUM
$42M
This Fund
S&P 500
This Quarter
Est. Return
-9%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$353M
AUM Growth
+$12.9M
(+3.8%)
Cap. Flow
+$60.9M
Cap. Flow
% of AUM
17.29%
Top 10 Holdings %
Top 10 Hldgs %
42.16%
Holding
101
New
22
Increased
19
Reduced
17
Closed
34
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Biohaven
BHVN
|
+$8.16M |
| 2 |
RxSight
RXST
|
+$7.8M |
| 3 |
Establishment Labs
ESTA
|
+$7.58M |
| 4 |
Capricor Therapeutics
CAPR
|
+$7.52M |
| 5 |
CMPS
Compass Pathways
CMPS
|
+$7.22M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vera Therapeutics
VERA
|
+$11.2M |
| 2 |
Vaxcyte
PCVX
|
+$8.23M |
| 3 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
+$6.49M |
| 4 |
iRhythm Holdings
IRTC
|
+$6.38M |
| 5 |
Sarepta Therapeutics
SRPT
|
+$5.27M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 91% |
| 2 | Consumer Staples | 0.08% |
| 3 | Consumer Discretionary | 0% |
| 4 | Industrials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
ADMA Biologics
ADMA
$2.04B
| $23.9M | 6.79% |
1,395,000
+35,000
| +3% | +$658K |
|
|
2
Vera Therapeutics
VERA
$2.39B
| $18.3M | 5.18% |
432,000
-252,000
| -37% | -$11.2M |
|
|
3
Sarepta Therapeutics
SRPT
$1.63B
| $15.4M | 4.38% |
127,000
-43,000
| -25% | -$5.27M |
|
4
Zevra Therapeutics
ZVRA
$575M
| $15.4M | 4.38% |
1,850,000
+150,000
| +9% | +$1.28M |
|
|
5
Establishment Labs
ESTA
$2.7B
| $14.1M | 3.99% |
305,000
+174,000
| +133% | +$7.58M |
|
|
6
CALL
Establishment Labs
ESTA
$2.7B
| $13.8M | 3.92% |
+300,000
| New | +$13.1M |
|
7
CALL
Scholar Rock
SRRK
$5.92B
| $13M | 3.68% |
+300,000
| New | +$9.77M |
|
8
Edwards Lifesciences
EW
$48.2B
| $12.2M | 3.46% |
165,000
-57,000
| -26% | -$3.99M |
|
9
Xenon Pharmaceuticals
XENE
$6.28B
| $11.3M | 3.2% |
288,000
-72,600
| -20% | -$3M |
|
|
SLNO
10
DELISTED
Soleno Therapeutics
SLNO
| $11.2M | 3.19% |
250,000
+37,091
| +17% | +$1.92M |
|
|
11
Capricor Therapeutics
CAPR
$380M
| $9.85M | 2.79% |
714,000
+429,000
| +151% | +$7.52M |
|
|
12
RxSight
RXST
$250M
| $9.8M | 2.78% |
285,000
+173,000
| +154% | +$7.8M |
|
13
Merit Medical Systems
MMSI
$4.67B
| $9.67M | 2.74% |
100,000
+15,000
| +18% | +$1.49M |
|
|
14
Biohaven
BHVN
$2.07B
| $9.34M | 2.65% |
250,000
+175,000
| +233% | +$8.16M |
|
15
Insmed
INSM
$22.6B
| $9.11M | 2.58% |
132,000
+2,000
| +2% | +$144K |
|
16
Rezolute
RZLT
$474M
| $8.3M | 2.35% |
1,694,000
-6,000
| -0.4% | -$30.2K |
|
17
Evolus
EOLS
$410M
| $7.56M | 2.15% |
685,000
+330,000
| +93% | +$4.64M |
|
|
ITCI
18
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $6.26M | 1.78% |
75,000
-79,000
| -51% | -$6.49M |
|
19
argenx
ARGX
$54.6B
| $6.15M | 1.74% |
+10,000
| New | +$5.86M |
|
20
Glaukos
GKOS
$8.89B
| $6M | 1.7% |
40,000
-37,000
| -48% | -$5.1M |
|
21
ResMed
RMD
$30.3B
| $5.95M | 1.69% |
+26,000
| New | +$6.26M |
|
22
Viking Therapeutics
VKTX
$3.93B
| $5.88M | 1.67% |
146,000
+20,000
| +16% | +$1.14M |
|
|
EXAS
23
DELISTED
Exact Sciences
EXAS
| $5.62M | 1.59% |
+100,000
| New | +$6.22M |
|
24
Pulmonx
LUNG
$52.8M
| $5.53M | 1.57% |
815,000
+315,000
| +63% | +$2.07M |
|
|
CMPS
25
Compass Pathways
CMPS
$1.46B
| $5.38M | 1.53% |
+1,424,400
| New | +$7.22M |
|
Similar funds
TA
SIM
LSA
VEPM
GC
VI
BCM
VAM
Altium Capital Management's Q4 2024 Portfolio in Review
As of Q4 2024, Altium Capital Management held 101 positions worth $353M, up 3.8% from $340M the previous quarter. Its ten largest holdings account for 42% of the portfolio.
Altium Capital Management deployed $60.9M of net new capital in Q4 2024, opening 22 new positions and adding to 19 existing holdings. Its largest new stake was Compass Pathways: 1,424,400 shares worth $5.38M.
By sector, the portfolio is most concentrated in Healthcare at 91% of assets, down from 97% a quarter earlier, followed by Consumer Staples and Consumer Discretionary.
On the sell side, the largest reduction was Vera Therapeutics, an estimated $11.2M trimmed.
- Altium Capital Management's largest Q4 2024 buy was Compass Pathways: 1,424,400 shares worth $5.38M.
- Altium Capital Management added most to Biohaven in Q4 2024, an estimated $8.16M increase.
- Altium Capital Management's biggest Q4 2024 reduction was Vera Therapeutics, cutting an estimated $11.2M.
- Altium Capital Management fully exited Vaxcyte in Q4 2024, selling an estimated $8.23M.
- Altium Capital Management's ten largest holdings make up 42% of its $353M portfolio in Q4 2024.
- Altium Capital Management opened 22 new positions and closed 34 in Q4 2024.
- Altium Capital Management's portfolio value rose 3.8% quarter-over-quarter to $353M.
Based on Altium Capital Management's 13F filing for Q4 2024, filed 13 Feb 2025.